Last reviewed · How we verify
Pamiparib capsule
Pamiparib inhibits poly(ADP-ribose) polymerase (PARP), preventing DNA repair and causing cancer cell death.
Pamiparib inhibits poly(ADP-ribose) polymerase (PARP), preventing DNA repair and causing cancer cell death. Used for Ovarian cancer (BRCA-mutated or HRD-positive), Breast cancer (BRCA-mutated), Gastric cancer (HRD-positive).
At a glance
| Generic name | Pamiparib capsule |
|---|---|
| Also known as | BGB-290 |
| Sponsor | BeiGene |
| Drug class | PARP inhibitor |
| Target | PARP1/PARP2 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Pamiparib is a PARP inhibitor that blocks the enzyme responsible for repairing single-strand DNA breaks in cancer cells. By inhibiting PARP, the drug causes accumulation of DNA damage, leading to cell death. It is particularly effective in tumors with homologous recombination deficiency (HRD), such as BRCA-mutated cancers.
Approved indications
- Ovarian cancer (BRCA-mutated or HRD-positive)
- Breast cancer (BRCA-mutated)
- Gastric cancer (HRD-positive)
Common side effects
- Anemia
- Nausea
- Fatigue
- Thrombocytopenia
- Leukopenia
Key clinical trials
- Maintenance Treatment With BGB-290 Versus Placebo in Participants With Platinum-sensitive Recurrent Ovarian Cancer (PHASE3)
- Study of the Efficacy, Safety and Pharmacokinetics of Pamiparib (BGB-290) in Participants With Advanced Solid Tumors (PHASE1, PHASE2)
- Study to Assess Safety, Tolerability and Clinical Activity of BGB-290 in Combination With Temozolomide (TMZ) in Participants With Locally Advanced or Metastatic Solid Tumors (PHASE1)
- Pamiparib Combined With Surufatinib for the Neoadjuvant Treatment of Unresectable Ovarian Cancer (PHASE2)
- Pamiparib (BGB-290) Was Used in EGFR-TkIs Resistant Non-small Cell Lung Cancer (PHASE1)
- Pamiparib in Fusion Positive, Reversion Negative High Grade Serous Ovarian Cancer or Carcinosarcoma With BRCA1/2 Gene Mutations If Progression on Substrate Poly ADP Ribose Polymerase Inhibitbor (PARPI) or Chemotherapy (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Pamiparib capsule CI brief — competitive landscape report
- Pamiparib capsule updates RSS · CI watch RSS
- BeiGene portfolio CI